These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 25726701)

  • 1. Introduction: on-label and off-label drug use in reproductive medicine.
    Legro RS
    Fertil Steril; 2015 Mar; 103(3):581-2. PubMed ID: 25726701
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Are "off-labels" legal?
    Price EC
    Mich Health Hosp; 1998; 34(6):20-1. PubMed ID: 10187136
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Quality of evidence in drug compendia supporting off-label use of typical and atypical antipsychotic medications.
    Paczynski RP; Alexander GC; Chinchilli VM; Kruszewski SP
    Int J Risk Saf Med; 2012 Jan; 24(3):137-46. PubMed ID: 22936056
    [TBL] [Abstract][Full Text] [Related]  

  • 4. United States v. Caronia: Off-Label Drug Promotion and First Amendment Balancing.
    Rabinowitz DP
    Fordham Law Rev; 2018 Apr; 86(5):2595-623. PubMed ID: 29993225
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Unapproved uses of approved drugs: the physician, the package insert, and the Food and Drug Administration: subject review. American Academy of Pediatrics Committee on Drugs.
    Pediatrics; 1996 Jul; 98(1):143-5. PubMed ID: 8668390
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effect of federal and state off-label marketing investigations on drug prescribing: The case of olanzapine.
    Wang B; Studdert DM; Sarpatwari A; Franklin JM; Landon J; Kesselheim AS
    PLoS One; 2017; 12(4):e0175313. PubMed ID: 28388667
    [TBL] [Abstract][Full Text] [Related]  

  • 7. U.S. physician knowledge of the FDA-approved indications and evidence base for commonly prescribed drugs: results of a national survey.
    Chen DT; Wynia MK; Moloney RM; Alexander GC
    Pharmacoepidemiol Drug Saf; 2009 Nov; 18(11):1094-100. PubMed ID: 19697444
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Off-label uses of drugs and medical devices: should the FDA crack down?
    Margolis RE
    Healthspan; 1993 Jan; 10(1):18-9. PubMed ID: 10124289
    [No Abstract]   [Full Text] [Related]  

  • 9. The use of Food and Drug Administration--approved medications for unlabeled (off-label) uses. The legal and ethical implications.
    Torres A
    Arch Dermatol; 1994 Jan; 130(1):32-6. PubMed ID: 8285737
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Outdated Prescription Drug Labeling: How FDA-Approved Prescribing Information Lags Behind Real-World Clinical Practice.
    Shea MB; Stewart M; Van Dyke H; Ostermann L; Allen J; Sigal E
    Ther Innov Regul Sci; 2018 Nov; 52(6):771-777. PubMed ID: 29714570
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Off-label prescribing explained. Why your doctor may recommend meds that aren't FDA-approved for your condition.
    Johns Hopkins Med Lett Health After 50; 2011 Jun; 23(4):7. PubMed ID: 21702115
    [No Abstract]   [Full Text] [Related]  

  • 12. Origins of the prohibition against off-label promotion.
    Coleman TS
    Food Drug Law J; 2014; 69(2):161-236, i. PubMed ID: 25163210
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Off-label or off-limits?
    Ratner M; Gura T
    Nat Biotechnol; 2008 Aug; 26(8):867-75. PubMed ID: 18688236
    [No Abstract]   [Full Text] [Related]  

  • 14. Criminalizing knowledge: the perverse implications of the intended use regulations of off-label promotion prosecutions.
    Gentry G
    Food Drug Law J; 2009; 64(3):441-58. PubMed ID: 19999637
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The major role of clinicians in the discovery of off-label drug therapies.
    Demonaco HJ; Ali A; Hippel Ev
    Pharmacotherapy; 2006 Mar; 26(3):323-32. PubMed ID: 16503712
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Off-label use of medical products in radiation therapy: summary of the report of AAPM Task Group No. 121.
    Thomadsen BR; Heaton HT; Jani SK; Masten JP; Napolitano ME; Ouhib Z; Reft CS; Rivard MJ; Robin TT; Subramanian M; Suleiman OH
    Med Phys; 2010 May; 37(5):2300-11. PubMed ID: 20527564
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Commercial speech and off-label drug uses: what role for wide acceptance, general recognition and research incentives?
    Gilhooley M
    Am J Law Med; 2011; 37(2-3):258-77. PubMed ID: 21847881
    [TBL] [Abstract][Full Text] [Related]  

  • 18. FDA Modernization Act: implications for oncology.
    Morris L
    Oncology (Williston Park); 1998 Nov; 12(11A):139-41. PubMed ID: 10028506
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Off-label uses of drugs in children.
    Blumer JL
    Pediatrics; 1999 Sep; 104(3 Pt 2):598-602. PubMed ID: 10469797
    [No Abstract]   [Full Text] [Related]  

  • 20. Intended and unintended consequences of the gabapentin off-label marketing lawsuit among patients with bipolar disorder.
    Chace MJ; Zhang F; Fullerton CA; Huskamp HA; Gilden D; Soumerai SB
    J Clin Psychiatry; 2012 Nov; 73(11):1388-94. PubMed ID: 23146199
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.